TFS Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

TFS Capital’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-21,668	Closed	-$121K	–	1049
2016 Q2	$121K	Sell	21,668 -174,403	-89%	-$1.11M	0.02%	836
2016 Q1	$1.05M	Buy	196,071 +179,024	+1,050%	+$1.04M	0.15%	239
2015 Q4	$148K	Sell	17,047 -37,276	-69%	-$314K	0.02%	614
2015 Q3	$456K	Sell	54,323 -96,489	-64%	-$1.54M	0.04%	543
2015 Q2	$2.66M	Buy	150,812 +32,829	+28%	+$422K	0.26%	95
2015 Q1	$1.36M	Buy	117,983 +99,898	+552%	+$1.16M	0.13%	237
2014 Q4	$182K	Buy	18,085 +3,779	+26%	+$19.1K	0.02%	828
2014 Q3	$65K	Sell	14,306 -496	-3%	-$2.66K	0.01%	992
2014 Q2	$100K	Buy	14,802 +310	+2%	+$2.34K	0.01%	1050
2014 Q1	$186K	Buy	+14,492	New	+$160K	0.01%	1207

Other funds holding SRNE

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

TFS Capital's SRNE Position: Q3 2016 in Review

TFS Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2016, closing a stake of 21,668 shares — an estimated $121K sold.

TFS Capital first reported a position in SRNE in Q1 2014 and held it in 10 quarters. The position peaked at $2.66M in Q2 2015. 62 funds tracked by Wall St. Rank hold SRNE as of Q3 2016.

TFS Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 21,668 Sorrento Therapeutics, Inc. shares in Q3 2016, an estimated $121K.
TFS Capital first reported a position in Sorrento Therapeutics, Inc. in Q1 2014 and held it in 10 quarters.
TFS Capital's Sorrento Therapeutics, Inc. position peaked at $2.66M in Q2 2015.
62 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.